Literature DB >> 8636419

In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia.

E Noiri1, T Peresleni, F Miller, M S Goligorsky.   

Abstract

Gene products of all three distinct nitric oxide synthases are present in the mammalian kidney. This mosaic topography of nitric oxide synthase (NOS) isoforms probably reflects distinct functional role played by each enzyme. While nitric oxide (NO) is cytotoxic to isolated renal tubules, inhibition of NO production in vivo invariably results in the aggravation of renal dysfunction in various models of acute renal failure. We reasoned that the existing ambiguity on the role of nitric oxide in acute renal failure is in part due to the lack of selective NOS inhibitors. Phosphorothioated derivatives of antisense oligodeoxynucleotides targeting a conserved sequence within the open reading frame of the cDNA encoding the inducible NOS (iNOS) were designed to produce a selective knock-down of this enzyme. In vivo use of these antisense constructs attenuated acute renal failure in rats subjected to renal ischemia. This effect was due, at least in part, to the rescue of tubular epithelium from lethal injury. Application of antisense constructs did not affect endothelial NOS, as evidenced by a spared NO release after the infusion of bradykinin during in vivo monitoring with an NO-selective microelectrode. In conclusion, the data provide direct evidence for the cytotoxic effects of NO produced via iNOS in the course of ischemic acute renal failure, and offer a novel method to selectively prevent the induction of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636419      PMCID: PMC507319          DOI: 10.1172/JCI118681

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

Review 1.  Inflammation, immunoregulation, and inducible nitric oxide synthase.

Authors:  A K Nussler; T R Billiar
Journal:  J Leukoc Biol       Date:  1993-08       Impact factor: 4.962

Review 2.  Approaches toward selective inhibition of nitric oxide synthase.

Authors:  M A Marletta
Journal:  J Med Chem       Date:  1994-06-24       Impact factor: 7.446

Review 3.  Nitric oxide synthases in mammals.

Authors:  R G Knowles; S Moncada
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

4.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids.

Authors:  L C Green; D A Wagner; J Glogowski; P L Skipper; J S Wishnok; S R Tannenbaum
Journal:  Anal Biochem       Date:  1982-10       Impact factor: 3.365

5.  Superoxide and peroxynitrite in atherosclerosis.

Authors:  C R White; T A Brock; L Y Chang; J Crapo; P Briscoe; D Ku; W A Bradley; S H Gianturco; J Gore; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

6.  Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.

Authors:  P A Cossum; H Sasmor; D Dellinger; L Truong; L Cummins; S R Owens; P M Markham; J P Shea; S Crooke
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

7.  Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury.

Authors:  Y Shi; A Fard; A Galeo; H G Hutchinson; P Vermani; G R Dodge; D J Hall; F Shaheen; A Zalewski
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

8.  Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation.

Authors:  D Salvemini; K Seibert; J L Masferrer; T P Misko; M G Currie; P Needleman
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Nitric oxide: a mediator in rat tubular hypoxia/reoxygenation injury.

Authors:  L Yu; P E Gengaro; M Niederberger; T J Burke; R W Schrier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

10.  The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine.

Authors:  J B Weinberg; D L Granger; D S Pisetsky; M F Seldin; M A Misukonis; S N Mason; A M Pippen; P Ruiz; E R Wood; G S Gilkeson
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  51 in total

1.  An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury.

Authors:  E Noiri; T Yokomizo; A Nakao; T Izumi; T Fujita; S Kimura; T Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 2.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

Review 3.  Hyperfiltration, nitric oxide, and diabetic nephropathy.

Authors:  David Z Levine
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

Review 4.  Gene therapy targeting kidney diseases: routes and vehicles.

Authors:  Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

5.  Anti-CD47 monoclonal antibody therapy reduces ischemia-reperfusion injury of renal allografts in a porcine model of donation after cardiac death.

Authors:  Min Xu; Xuanchuan Wang; Babak Banan; Danielle L Chirumbole; Sandra Garcia-Aroz; Aparna Balakrishnan; Deepak K Nayak; Zhengyan Zhang; Jianluo Jia; Gundumi A Upadhya; Joseph P Gaut; Ronald Hiebsch; Pamela T Manning; Ningying Wu; Yiing Lin; William C Chapman
Journal:  Am J Transplant       Date:  2017-12-02       Impact factor: 8.086

6.  Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice.

Authors:  C W Yang; C C Yu; Y C Ko; C C Huang
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

7.  Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.

Authors:  Daisuke Katagiri; Yoshifumi Hamasaki; Kent Doi; Koji Okamoto; Kousuke Negishi; Masaomi Nangaku; Eisei Noiri
Journal:  J Am Soc Nephrol       Date:  2013-10-03       Impact factor: 10.121

8.  IL-18 contributes to renal damage after ischemia-reperfusion.

Authors:  Huiling Wu; Melissa L Craft; Peng Wang; Kate R Wyburn; Gang Chen; Jin Ma; Brett Hambly; Steven J Chadban
Journal:  J Am Soc Nephrol       Date:  2008-09-24       Impact factor: 10.121

Review 9.  Immunopathophysiology of trauma-related acute kidney injury.

Authors:  David A C Messerer; Rebecca Halbgebauer; Bo Nilsson; Hermann Pavenstädt; Peter Radermacher; Markus Huber-Lang
Journal:  Nat Rev Nephrol       Date:  2020-09-21       Impact factor: 28.314

Review 10.  Gene therapy for renal disorders: what are the benefits for the elderly?

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.